Pfizer’s immunotherapy ELREXFIO approved in EU for multiple myeloma
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. ... Read More
FDA greenlights Pfizer’s ELREXFIO for advanced multiple myeloma treatment
Pfizer Inc. has earned accelerated approval from the U.S. Food and Drug Administration (FDA) for its innovative drug, ELREXFIO (elranatamab-bcmm). This drug aims to treat ... Read More